Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Author Profile

Aryeh Fischer, MD

Aryeh Fischer, MD
Chief, Division of Rheumatology
Associate Professor
Department of Medicine
National Jewish Health



1994 - 1998 University of Maryland School of Medicine, MD


  • 1998 - 2001 Temple University Hospital, Internal Medicine Internship and Residency
  • 2001 - 2002 Temple University Hospital, Chief Medical

Resident Fellowship

  • 2002 - 2004 University of Colorado Denver, Rheumatology

Fellowship Research Interests

Dr. Aryeh Fischer is Acting Chief of Rheumatology, Co-Director of the Autoimmune Lung Center, and Associate Professor of Medicine at National Jewish Health. Dr. Fischer has strong clinical and research interests involving autoimmune lung disease and connective tissue disease associated - interstitial lung disease and pulmonary arterial hypertension in particular. Dr. Fischer has served as an invited lecturer on autoimmune lung disease at numerous national and international medical conferences and has published numerous original research articles, review articles and textbook chapters within these arenas. Dr. Fischer also has clinical interests in other systemic autoimmune diseases, and systemic sclerosis (scleroderma) in particular.

Board Certification

  • 2004: American Board of Internal Medicine in Rheumatology
  • 2001: American Board of Internal Medicine

Professional Development

  • American College of Rheumatology
  • American Thoracic Society
  • Scleroderma Foundation: Medical Advisory Board Member
  • Pulmonary Fibrosis Foundation: Medical Advisory Board Member


Fischer A, Interstitial Lung Disease: A Rheumatologist’s Perspective. Journal of Clinical Rheumatology 2009. 15(2):95-99.

Fischer A, Swigris JJ, West SG, Brown KK, du Bois R M. Connective Tissue Disease Associated Interstitial Lung Disease: A call for clarification. Chest 2010;138 251-256.

Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, Huie TJ, Stevens AD, Gill MB, Rabinovitch AM, Lynch DA, Burns DA, Pineiro IS, Groshong SD, Duarte Achcar RD, Brown KK, Martin RJ, Swigris JJ. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respiratory Medicine. 2012 Jul;106(7):1040-7.

Fischer A, Bull TM, Steen VD. A practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Research. 2012 ; 64 (3):303–310.

Fischer A & du Bois RM. Interstitial Lung Disease in Connective Tissue Disorders: Prognosis and Therapeutic Dilemmas. The Lancet. In Press.


Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, National Jewish Health


Director, Scleroderma Clinic, University of Colorado.

Profile Photo


  • Evaluation and Management of Connective Tissue Disease-Associated Interstitial Lung Disease There are complex interactions between connective tissue disease (CTD) and interstitial lung disease (ILD), particularly in the PH patient. Clinicians that care for these patients will benefit from a deeper understanding of CTD and the ILD aspects of this diverse spectrum of disease. There are many clinical dilemmas to address and this course will focus on an approach to the evaluation and management of CTD-associated ILD.
  • Screening Systemic Sclerosis Patients for Pulmonary Arterial Hypertension This course will describe the role for inotropic and vasopressor therapy in acute decompensated right ventricular (RV) failure, list the limitations of inotropic and vasopressor therapy, and discuss the use of other potential therapies in RV failure.